Integra's Tissue Reconstruction Unit Clears Goodwill Test With 11.3% To Spare, A Year After $511.4 Million Write-Off

Integra's 10-Q shows Neurosurgery has a wider 15.3% cushion, and both units stayed above carrying value in a stress test.

Share
Integra's Tissue Reconstruction Unit Clears Goodwill Test With 11.3% To Spare, A Year After $511.4 Million Write-Off

Integra LifeSciences, a medical device maker, said in its 10-Q that its Tissue Reconstruction unit passed this year's goodwill test with 11.3% headroom, the thinner of its two cushions. Neurosurgery cleared with 15.3%, and the filing came a year after the company wrote off $511.4 million of goodwill.

Two cushions, one stress test

Goodwill is the premium a company paid for acquired businesses; headroom is how far a unit's estimated fair value sits above its carrying value. Both units were tested at a 13.0% discount rate and 2.5% terminal growth, and neither needed an impairment charge.

The company also ran a hypothetical: raise the discount rate by 50 basis points (half a percentage point) and cut terminal growth by the same amount. That would reduce fair value by 3.8% for Tissue Reconstruction and 3.0% for Neurosurgery. Both would still sit above carrying value, the company said.

Tissue Reconstruction carried $267.8 million of goodwill at September 30, 2026, down from $271.0 million at the end of 2025 on currency translation. Specialty Surgery, which includes Neurosurgery, carried $340.1 million.

A harder test than last time

This year both units were tested quantitatively, with the company choosing to skip the softer qualitative review. The prior quarter's filing said last year's third-quarter annual test was qualitative, with no quantitative test needed. The 2025 impairment test used a 13.5% rate.

The Codman tradename, carried at $175.1 million, was also tested quantitatively, at a 14.0% discount rate versus 14.5% in the 2025 test. No impairment was recorded.

Where the softness sits

Tissue Reconstruction revenue fell 2% to $107.1 million in the third quarter, with lower sales of MicroMatrix and Integra Skin offsetting growth in PriMatrix and DuraSorb. For nine months the segment rose 1% to $325.3 million.

CEO Stuart Essig, in the earnings release, cited "softer-than-expected results in Tissue Reconstruction" and "more measured expectations for portions of our Tissue Reconstruction business." Specialty Surgery revenue rose 4% to $304.1 million, despite about $7 million lost to the Cincinnati flood.

The company reported third-quarter net income of $14.9 million, against a $5.4 million loss a year earlier. Integra's market value was $959 million at Friday's close.

The company's 10-Q puts the Tissue Reconstruction cushion at 11.3% and says a combined 50-basis-point shift in its two key assumptions would take 3.8% off fair value.

Sources

More on Integra LifeSciences

All Integra LifeSciences (IART) coverage →